Side-by-side comparison of AI visibility scores, market position, and capabilities
Pawtucket RI toys and games (NASDAQ: HAS) at $4.136B FY2024 revenue (-17% post-eOne divestiture); record 20.3% operating margins, $847M operating cash flow, Magic: The Gathering + Monopoly + Transformers competing with Mattel.
Hasbro, Inc. is a Pawtucket, Rhode Island-based global play and entertainment company — publicly traded on NASDAQ (NASDAQ: HAS) as an S&P 500 Consumer Discretionary component — designing, manufacturing, and marketing branded toys, games, licensed products, and tabletop gaming experiences under iconic brands including My Little Pony, Transformers, G.I. Joe, Play-Doh, Peppa Pig, Dungeons & Dragons, Magic: The Gathering, Monopoly, Scrabble, Risk, Trivial Pursuit, and Battleship through approximately 6,000 employees worldwide. In fiscal year 2024, Hasbro delivered record adjusted operating profit of $839 million and record operating margins of 20.3%, while revenue declined 17% to $4.136 billion — reflecting the planned reduction following the completion of the Entertainment One (eOne) film and television production business divestiture (sold to Lionsgate Entertainment in 2023 for $500 million, unwinding the $4.6 billion eOne acquisition of 2019). Excluding the eOne impact, core Consumer Products (toys, games, and licensed products) and Wizards of the Coast (tabletop games, including Magic: The Gathering and Dungeons & Dragons) segments demonstrated improved profitability. The company generated $847 million in operating cash flow, paid $390 million in dividends, reduced debt by $83 million, and achieved $370 million in gross cost savings — reflecting CEO Chris Cocks' "Hasbro Simplified" portfolio restructuring strategy that focuses the company on its highest-returning brands and digital gaming opportunities. Magic: The Gathering remains one of the most valuable entertainment franchises globally, with 40+ million players and digital extensions (Magic: The Gathering Arena) that provide recurring digital revenue.
Skillman NJ consumer health (NYSE: KVUE) ~$15.5B FY2024 revenue; J&J spinoff May 2023, Tylenol/Band-Aid/Neutrogena/Listerine/Aveeno portfolio, talc litigation exposure competing with Haleon and P&G.
Kenvue Inc. is a Skillman, New Jersey-based consumer health company — publicly traded on the New York Stock Exchange (NYSE: KVUE) as an S&P 500 Consumer Staples component — marketing and selling over-the-counter medicines, skin health and beauty products, and essential health products through iconic consumer brands including Tylenol (pain and fever relief), Band-Aid (wound care), Neutrogena (skin care), Johnson's (baby care), Listerine (oral care), Aveeno (skincare), Motrin/Advil (ibuprofen pain relief), Zyrtec (allergy), Nicorette (smoking cessation), Neosporin (antibiotic ointment), and Benadryl through approximately 22,000 employees in 165 countries. Kenvue was separated from Johnson & Johnson through an IPO in May 2023 (the largest US IPO of 2023) and a tax-free distribution of J&J's remaining 89.6% stake to J&J shareholders in August 2023 — creating the world's largest pure-play consumer health company by market capitalization, with J&J retaining no ownership. In fiscal year 2024, Kenvue reported revenues of approximately $15.5 billion, with organic growth facing headwinds from lower cold/cough/flu season severity (Tylenol, Zyrtec, Benadryl volume sensitive to respiratory illness intensity), competitive pressure in skin health (Neutrogena competing with Korean beauty brands, Cerave, and pharmacy private label), and macroeconomic consumer trading down to lower-price alternatives in some markets. CEO Thibaut Mongon leads Kenvue's strategy of investing in the brand superiority of its household name portfolio while improving operational efficiency in the post-spinoff period (implementing Kenvue's own supply chain infrastructure, IT systems, and organizational structure previously shared with J&J).
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.